A patient I’m seeing — third trimester, severe anhedonia, no sleep in weeks, husband terrified — asked me last month whether there was “a pill” she could take that would work fast. Not in six weeks. Fast. I told her the honest answer: the only rapid-acting antidepressant with robust evidence and an FDA approval was delivered intravenously or intranasally, not orally. The oral version she was hoping for was still in trials.
Lipocine’s LPCN 1154 was supposed to change that answer. It didn’t.
The Utah biotech announced that its oral brexanolone formulation failed to separate from placebo in a Phase 3 postpartum depression trial. Shares fell 77% on the news. The loss stings because the logic was sound: brexanolone (Zulresso), Sage Therapeutics’ intravenous GABA-A modulator, received FDA approval for postpartum depression and demonstrated that rapid neuroactive steroid modulation could produce clinical responses in days rather than weeks. An oral version with equivalent pharmacokinetics would have been genuinely practice-changing. But pharmacokinetics is exactly where the oral formulation ran into trouble — achieving the plasma concentrations needed to drive the same GABA-A positive allosteric modulation that makes IV brexanolone work is an absorption problem that Lipocine’s formulation couldn’t solve at the Phase 3 level.
The Bioavailability Wall
The neuroactive steroid space has been chasing oral delivery for years, and the failure pattern is instructive. Sage Therapeutics and Biogen’s zuranolone — a synthetic neuroactive steroid — did reach FDA approval in 2023 for both postpartum depression and major depressive disorder, becoming the first oral rapid-acting antidepressant approved in the U.S. But zuranolone’s approval came with a narrower label than sponsors initially sought, and the drug is a 14-day course, not a chronic therapy. The commercial uptake has been slower than analysts projected. Meanwhile, LPCN 1154’s failure suggests that reformulating an IV neuroactive steroid into an oral product doesn’t simply inherit the parent compound’s efficacy — the CNS exposure has to be replicated precisely, and the gut-liver axis makes that a genuine engineering challenge, not just a formulation detail.
What the pipeline still underweights is how often these patients present with comorbid anxiety, trauma history, or substance use — populations that neuroactive steroid trials have historically excluded. In my practice, perinatal patients with treatment-resistant presentations frequently carry a dual-diagnosis burden: prior trauma, alcohol use disorder in partial remission, or a history of benzodiazepine dependence that makes GABAergic approaches complicated to manage. The clean Phase 3 population doesn’t reflect the patient sitting across from me.
Which is where rapid-acting glutamatergic mechanisms become clinically relevant in a way the postpartum depression field hasn’t fully engaged. Ketamine and esketamine’s NMDA antagonism produces antidepressant effects within hours, independent of the HPA-axis dysregulation that characterizes perinatal mood disorders. Having treated thousands of patients with ketamine-based approaches across mood disorder indications, the response profile in treatment-resistant cases — rapid onset, durability with maintenance dosing, tolerability in medically complex patients — is not anecdotal. The Journal of Affective Disorders published outcomes data on over 1,000 patients treated through our program, and the response rates in patients who had failed two or more prior antidepressants were clinically meaningful. Perinatal patients are underrepresented in that literature, partly because sponsors have been waiting to see whether the oral neuroactive steroid field would solve the accessibility problem first.
The Protocol Gap Sponsors Haven’t Closed
Lipocine’s failure accelerates a reckoning that was already coming. The postpartum depression trial design problem isn’t just pharmacokinetic — it’s that most protocols still treat “postpartum depression” as a homogeneous diagnosis. Severity at baseline, prior treatment history, co-occurring anxiety, and time since delivery all drive response heterogeneity in ways that a single primary endpoint — typically the Hamilton Depression Rating Scale at day 15 — can’t capture cleanly. Zuranolone’s Phase 3 program navigated this partly by enrolling patients with higher baseline severity, which enriched the responder population. LPCN 1154’s protocol details aren’t fully public, but the placebo separation failure in a well-characterized indication is a signal worth studying, not just mourning.
From a site operations perspective, perinatal patients are among the most challenging to retain in outpatient trial settings — not because they’re unwilling, but because the logistical burden of new motherhood intersects badly with rigid visit schedules and in-person consent requirements. Telehealth-capable sites with flexible scheduling and bilingual consent infrastructure retain this population at meaningfully higher rates. The Spanish-speaking perinatal patients in my practice face a compounded barrier: nearly every postpartum depression trial runs English-only consent, which systematically excludes a population with documented higher rates of perinatal mood disorders and lower rates of treatment access.
The next signal I’m watching is Sage and Biogen’s commercial data on zuranolone through mid-2026 — real-world prescription patterns will tell us whether the oral rapid-acting category has a market problem or a pipeline problem. If uptake remains slow despite an approved product, the next-generation trial designs for this indication need to rethink who they’re actually building for.
References
- Endpoints News — “Lipocine’s postpartum depression drug fails; AstraZeneca claims liver cancer win” (April 2026)
- Journal of Affective Disorders — Vando et al., ketamine treatment outcomes in mood disorders (2023)
- FDA Drug Approval — Zulresso (brexanolone) IV for postpartum depression, Sage Therapeutics
- FDA Drug Approval — Zuranolone (Zurzuvae) for postpartum depression and major depressive disorder, Sage Therapeutics/Biogen (2023)
- FDA Drug Approval — Spravato (esketamine) nasal spray for treatment-resistant depression, Janssen (2019)
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
